Home Newsfeeds Oppenheimer Initiates Coverage On Day One Biopharmaceutical with Perform Rating

Oppenheimer Initiates Coverage On Day One Biopharmaceutical with Perform Rating

Oppenheimer analyst Matthew Biegler initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Perform rating.

byBenzinga Newsdesk

February 3, 2023

1 minute read

Oppenheimer analyst Matthew Biegler initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Perform rating.

Rosenblatt Maintains Buy on Manhattan Associates, Lowers Price Target to $150

By Benzinga Newsdesk

July 22, 7:22 AM

Rosenblatt analyst Blair Abernethy maintains Manhattan Associates (NASDAQ:MANH) with a Buy and lowers the price target from $165 to $150.

MANH

Compass Therapeutics Provides Corporate Update

By Benzinga Newsdesk

January 5, 9:11 AM

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Consistent with

CMPX

Tesla Q4 Earnings Preview: Earnings Estimates, What Analysts Are Saying, Cybertruck Remains Key Focus Of Shareholders

By Chris Katje

January 22, 3:50 PM

A look at the key items analysts and investors are watching ahead of the fourth quarter earnings report from Tesla.

TSLA

Crude Oil Rises By More Than 2%; Codexis Shares Plummet

By Lisa Levin

July 15, 3:05 PM

U.S. stocks traded higher toward the end of trading, following the release of several earnings results and economic reports.

Oppenheimer Initiates Coverage On Day One Biopharmaceutical with Perform Rating

Related Posts

Rosenblatt Maintains Buy on Manhattan Associates, Lowers Price Target to $150

Compass Therapeutics Provides Corporate Update

Tesla Q4 Earnings Preview: Earnings Estimates, What Analysts Are Saying, Cybertruck Remains Key Focus Of Shareholders

Crude Oil Rises By More Than 2%; Codexis Shares Plummet